Clinical Trials

Introduction to Clinical Trials

This is a selection of our current Clinical Trials.

Oryzon - Ethereal Study 

Mild to moderate Alzheimer's Disease
24 weeks study followed by an open label 24-week extension.

A multicentre, multinational, randomised, double-blind, placebo-controlled, 3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients with mild-moderate Alzheimer's Disease. ETHERAL Study

Inclusion

Exclusion

  • Age 50 - 85
  • MMSE 16-26
  • Treatment with cholinesterase inhibitors stable for 6 months prior to screen
  • Patients will need a study partner
  • Contraindications for MRI
  • Seizure disorders
  • Heart disease
  • Memantine use
  • Warfarin use
Contact us for further information

Cookies on our website

Cookies are used to ensure you get the best browsing experience. No personally identifiable information is collected.
By using our site you agree to these cookies being used. For more information please see our Cookie Policy.